Chronicle Bio, Inc.
About Chronicle Bio, Inc.
Chronicle Bio, Inc. is a techbio startup focused on radically accelerating insights on neuroimmune disorders through an AI-ready data platform targeting conditions like POTS, ME/CFS, and Long COVID. The company merges deep tech and biomedical science expertise and officially launched in August 2025. It operates in Drug Discovery, Other Healthcare Technology Systems, and Decision/Risk Analysis with verticals in Artificial Intelligence & Machine Learning, HealthTech, and Life Sciences. Headquarters are at 1080 O'Brien Drive, Suites A & B, Menlo Park, CA 94025.
- 🔗 ChronicleBio 2026 Company Profile: Valuation, Funding & Investors | PitchBook
- 🔗 SEC Form D/A - Chronicle Bio, Inc.
- 🔗 Chronicle Bio Valuation & Funding History | Caplight
- 🔗 Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions
- 🔗 ChronicleBio
Key highlights
- Raised $250k in private placement with $5M total offering amount per SEC filing.
- Focuses on AI-ready data platform for neuroimmune disorders including POTS, ME/CFS, and Long COVID.
- Led by founding team combining tech, healthcare, and life sciences expertise with Rishi Reddy as Co-founder & Executive Chairman.
- Venture capital-backed with investors including Breyer Capital and Electric Capital.
- Headcount of 22 employees as of latest data.
Ask StreetZero about Chronicle Bio, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account